- Home
- KROS vs XNCR Comparison
KROS vs XNCR Comparison
Compare KROS & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- XNCR
- Stock Information
- Founded
- KROS 2015
- XNCR 1997
- Country
- KROS United States
- XNCR United States
- Employees
- KROS N/A
- XNCR N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- KROS Health Care
- XNCR Health Care
- Exchange
- KROS Nasdaq
- XNCR Nasdaq
- Market Cap
- KROS 565.0M
- XNCR 547.8M
- IPO Year
- KROS 2020
- XNCR 2013
- Fundamental
- Price
- KROS $15.71
- XNCR $12.04
- Analyst Decision
- KROS Buy
- XNCR Buy
- Analyst Count
- KROS 14
- XNCR 11
- Target Price
- KROS $20.56
- XNCR $22.20
- AVG Volume (30 Days)
- KROS 370.6K
- XNCR 1.2M
- Earning Date
- KROS 11-05-2025
- XNCR 11-05-2025
- Dividend Yield
- KROS N/A
- XNCR N/A
- EPS Growth
- KROS N/A
- XNCR N/A
- EPS
- KROS 0.47
- XNCR N/A
- Revenue
- KROS $232,844,000.00
- XNCR $146,929,000.00
- Revenue This Year
- KROS $5,998.31
- XNCR $23.31
- Revenue Next Year
- KROS N/A
- XNCR N/A
- P/E Ratio
- KROS $33.68
- XNCR N/A
- Revenue Growth
- KROS 85820.30
- XNCR N/A
- 52 Week Low
- KROS $9.12
- XNCR $6.92
- 52 Week High
- KROS $72.37
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- KROS 53.11
- XNCR 80.54
- Support Level
- KROS $15.00
- XNCR $10.24
- Resistance Level
- KROS $16.57
- XNCR $12.63
- Average True Range (ATR)
- KROS 0.53
- XNCR 0.57
- MACD
- KROS -0.06
- XNCR 0.11
- Stochastic Oscillator
- KROS 47.77
- XNCR 76.73
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.